Used in the treatment of X-linked hypophosphatemia (XLH), this antibody targets fibroblast growth factor 23 (FGF23) to improve phosphate reabsorption in the kidneys. By neutralizing excess FGF23 activity, it helps increase serum phosphate levels and enhance bone mineralization in both children and adults. It is particularly effective in managing rickets and osteomalacia associated with XLH. Administered via subcutaneous injection, it supports improved mobility, reduced bone pain, and better growth in pediatric patients. Also under investigation for other FGF23-mediated disorders like tumor-induced osteomalacia (TIO).